Home Federal Bank of Tennessee continued to hold its position in shares of Bristol-Myers Squibb Co. (NYSE:BMY) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,915 shares of the biopharmaceutical company’s stock at the end of the second quarter. Home Federal Bank of Tennessee’s holdings in Bristol-Myers Squibb were worth $288,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Jolley Asset Management LLC raised its position in shares of Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 80 shares during the period. Univest Corp of Pennsylvania acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth about $202,000. Windsor Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth about $205,000. Oakwood Capital Management LLC CA acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth about $210,000. Finally, Verus Financial Partners Inc. acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth about $218,000. Hedge funds and other institutional investors own 72.87% of the company’s stock.
Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.86% during midday trading on Monday, reaching $49.34. The company had a trading volume of 11,577,968 shares. The firm’s 50-day moving average price is $54.82 and its 200 day moving average price is $66.24. Bristol-Myers Squibb Co. has a 12 month low of $49.10 and a 12 month high of $77.12. The firm has a market capitalization of $82.44 billion, a PE ratio of 28.85 and a beta of 0.75.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The company earned $4.90 billion during the quarter, compared to analyst estimates of $4.60 billion. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The firm’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.53 earnings per share. Equities analysts anticipate that Bristol-Myers Squibb Co. will post $2.63 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be paid a dividend of $0.38 per share. The ex-dividend date is Wednesday, October 5th. This represents a $1.52 annualized dividend and a yield of 3.08%. Bristol-Myers Squibb’s dividend payout ratio is presently 87.36%.
A number of research analysts have weighed in on the company. Jefferies Group raised their price objective on Bristol-Myers Squibb from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, July 14th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a report on Wednesday, July 13th. Berenberg Bank restated a “buy” rating on shares of Bristol-Myers Squibb in a report on Tuesday, July 12th. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 price objective on the stock in a report on Monday, July 25th. Finally, SunTrust Banks Inc. lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $86.00 to $68.00 in a report on Friday, August 5th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $69.06.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the completion of the sale, the director now directly owns 334,499 shares in the company, valued at $19,022,958.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.24% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.